10 Chlamydial STD- Statistics 90 million cases50-70% of patients initially asymptomatic: not treated40% of untreated females – pelvic inflammatory disease20% of PID cases- infertilityAdapted from STD statistics
15 Vaccines Against Chlamydial STD Major outer membrane protein (MOMP)Chlamydia-purified MOMPRecombinant MOMPMOMP DNAMOMP synthetic peptidesMOMP plus outer membrane protein 2 (omp2)Chlamydia-purified MOMP refolded to native configurationCons: MOMP - serovar-specificCurrently no licensed vaccine against C. trachomatisNeed for identification of new vaccine candidates
34 Summary CPAF vaccine administered with Th1 adjuvant: Enhances clearance of infectionProtects against severe pathologyInduces robust cellular IFN-g responseInduces systemic and mucosal antibodyProtection is dependent upon CPAF-specificcellular IFN-g responses but not antibody
36 Bench to Bedside Anti-Chlamydia vaccine Identification of pathogenic mechanismsVaccine antigen discoveryValidation of protection and pathogenesiscorrelates in clinical samplesRoutes, Delivery systemsAdjuvants, FormulationsNon-Human PrimatesClinical TrialsAnti-Chlamydia vaccine
Your consent to our cookies if you continue to use this website.